vinorelbine
Overview
Semisynthetic vinca alkaloid; used in maintenance and relapsed pediatric rhabdomyosarcoma regimens.
Evidence in the corpus
- Used in maintenance/relapsed regimens for extremity rhabdomyosarcoma in the 61-patient MSKCC 2000–2021 cohort spanning sequential COG/institutional protocols PMID:37315267.
- Mocetinostat + vinorelbine was one of the five matched-therapy regimens tested in the UCLA PDTO sarcoma clinical application cohort (n=5 patients); normalized organoid viability correlated with time-to-next-treatment across the matched cohort (R²=0.921, p=0.009). PMID:39305899
- Vinorelbine appears as part of NCCN-recommended RMS regimens (cyclophosphamide/doxorubicin/vinorelbine) in the UCLA sarcoma screen actionability mapping, recurring among the top-five NCCN hits for rhabdomyosarcoma. PMID:39305899
- Vinca alkaloid; usable from second trimester in pregnant young-onset NSCLC patients as part of platinum-based combination regimens; reviewed as pregnancy-compatible option PMID:27346245
- Used as the third-agent in adjuvant cisplatin/carboplatin plus vinorelbine regimens in the TRACERx NSCLC ctDNA study (NCT01888601); patients whose ctDNA failed to clear during adjuvant therapy recurred within 1 year, while ctDNA clearance was associated with sustained remission at 688 days. PMID:28445469
Resistance mechanisms
- Not reported in corpus.
Cancer types (linked)
Sources
PMID:39305899 — Duminuco et al. 2024, UCLA PDTO sarcoma screen; mocetinostat + vinorelbine in matched therapy; NCCN RMS regimen.
PMID:28445469 — Abbosh et al. 2017, Nature. TRACERx NSCLC ctDNA study; vinorelbine component of adjuvant cisplatin/carboplatin backbone; ctDNA clearance vs. resistance monitoring.
This page was processed by entity-page-writer on 2026-05-15.